Acorda Presents CVT-301 Results At International Congress of Parkinson’s Disease and Movement Disorders
Acorda Therapeutics, Inc. recently presented the results of its Phase 2b study of CVT-301, an inhaled levodopa (L-dopa)…
Articles by Ana de Barros, PhD
Amarantus Announces First Clinical Trial Site and Patient Enrollment in Phase 2b Study for Eltoprazine in Parkinson’s Disease Levodopa-Induced Dyskinesia
Amarantus BioScience Holdings, Inc, a company that develops diagnostics and treatments for syndromes in the fields of neurology, psychiatry,…
Cynapsus’ Parkinson’s Off-Episodes Therapy Granted US Patent
Cynapsus Therapeutics Inc. (CTH) has been granted an additional patent for its sublingual apomorphine portfolio by the U.S. Patent and Trademark Office…
Study Uncovers Specific Neural Cells Linked to Movement and Navigation in Space for Parkinson’s Disease
In a recent study published in the journal Neuron, a team of researchers at the University of…
NeuroDerm to Discuss Parkinson’s Therapy at Upcoming Conference
The CEO of NeuroDerm Ltd. has been invited to discuss the company’s achievements at the Jefferies 2015 Healthcare Conference, taking place next month in…
Amarantus Announces Positive Data on MANF Distribution in Pig Model of Parkinson’s Disease
Amarantus BioScience Holdings (AMBS), a company developing treatments and diagnostics for diseases in the areas of neurology, psychiatry, ophthalmology…
Xadago To Be Launched in Germany for Parkinson’s Disease
Italian pharmaceutical company Zambon S.p.A. and Newron Pharmaceuticals S.p.A. have announced plans to launch Xadago, a drug therapy for mid- to late-stage Parkinson’s…
Former Tigers Baseball Legend Kirk Gibson Diagnosed with Parkinson’s Disease
Former Detroit Tigers player Kirk Gibson was diagnosed with Parkinson’s disease after being submitted to a series of tests. The diagnosis…